
AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients
pharmafile | March 23, 2016 | News story | Research and Development | AstraZeneca, Brilinta, stroke
AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed to best once-daily 100mg aspirin in treating patients with acute ischaemic stroke or transient ischaemic attack (TIA).
The primary efficacy endpoint of the trial was time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial infarction (MI, also known as heart attack) and death.
Although fewer events were observed in patients on Brilinta (marketed as Brilique in Europe), the trend did not reach statistical significance.
Sean Bohen, executive vice president, Global Medicines Development and chief medical officer at AstraZeneca, says: “We will present the full analysis of the trial results, including subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data. The SOCRATES trial enrolled a patient population that differs from the currently-approved indications for Brilinta/Brilique.”
Joel Levy
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






